- Open Access
Monitoring response to gefitinib in nude mouse tumor xenografts by 18 F-FDG microPET-CT: correlation between 18 F-FDG uptake and pathological response
World Journal of Surgical Oncologyvolume 13, Article number: 111 (2015)
The purpose of this study is to investigate whether 18 F-fluorodeoxyglucose (FDG) micro-positron emission tomography-computed tomography (microPET-CT) can be used to monitor a metabolic response to gefitinib in nude mouse tumor xenografts.
Sixteen nude mice were implanted with human A431 epidermoid carcinoma cells and ten with human A549 lung adenocarcinoma cells, and the tumors were allowed to grow to an approximate size of 150 mm3. Ten and five of these mice, respectively, received intragastric gefitinib (100 mg/kg) once daily for 14 days, whereas six and five, respectively, received sterile water. Tumor metabolic activity was assessed by 18 F-FDG microPET imaging before treatment (day 0) and on days 2, 7, and 14. Tumor uptake of 18 F-FDG was determined from a region-of-interest drawn around the tumor, and the maximum percentage injected dose per gram (%ID/gmax) was calculated. Tumor volume measured on day 14 by microCT was used to categorize tumors as sensitive, stable, or resistant to gefitinib, and pathologic changes in these tumors were analyzed.
On day 2, the average changes in 18 F-FDG uptake by A431 tumors sensitive, stable, and resistant to gefitinib were −30.92% ± 6.66%, −5.68% ± 6.95%, and 7.72% ± 3.85%, respectively (P < 0.05 each), with no significant differences in the sizes of tumors sensitive and stable to gefitinib (P = 0.169). On day 7, sensitive tumors were significantly smaller than stable tumors (P = 0.034). On day 14, areas of necrosis were observed in gefitinib-sensitive tumors, with tumor necrosis ratios differing significantly among the sensitive, stable, and control groups (P < 0.05 each). In mice implanted with A549 cells, however, tumor 18 F-FDG uptake, volume, and percent necrosis did not differ significantly between gefitinib-treated and untreated mice on days 0, 2, 7, and 14 (P > 0.05 each).
F-FDG uptake is a sensitive method of detecting metabolic changes in tumors associated with therapy in vivo.
Epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have significant antitumor activities, with clinical benefits observed in patients with various tumor types [1-4]. Unfortunately, however, responses have been seen only in subgroups of patients [3,5], making it critical to select only those patients who could benefit from treatment with EGFR-TKIs.
Specific mutations in the K-RAS and EGFR genes (exons 18, 19, and 21) in tumors have been shown to be biomarkers of response to EGFR-TKI [6,7]. Although these genetic markers may be used to predict treatment outcome, these tests are invasive, unpleasant, and inconvenient for patients. During the course of treatment, it is difficult to repeatedly acquire appropriate tumor samples for monitoring responses to EGFR-TKI . There is a clear clinical need for noninvasive, safe, real-time, quantitative, and readily available approaches to monitor therapeutic responses to treatment, thus improving patient management.
Positron emission tomography (PET) imaging, which shows the early effects of treatment on tumor metabolism, has been widely used in the clinical management of patients with cancer. 18 F-fluorodeoxyglucose (FDG) PET-computed tomography (PET-CT) has been used to measure metabolic responses of tumor to treatment, including chemotherapy, radiotherapy, and targeted therapy [9,10]. Indeed, clinical trials have shown that 18 F-FDG PET-CT imaging may be a reliable surrogate marker of early therapeutic responses and clinical benefits .
Treatment of non-small cell lung cancer (NSCLC) cell lines sensitive to the EGFR-TKI gefitinib with this agent resulted in a decline in 18 F-FDG uptake within 2 h, before the inhibition of cellular proliferation and the induction of apoptosis . In addition, 18 F-FDG uptake by gefitinib-sensitive xenografts in mice began to decline as soon as 48 h after initial treatment with gefitinib. A recent evaluation in 20 patients with lung adenocarcinoma treated with gefitinib suggested that changes in tumor 18 F-FDG uptake may predict response and outcome . Patients who later exhibited longer progression-free survival (PFS) showed a 20% standardized uptake value (SUV) decrease in 18 F-FDG uptake after 2 days of gefitinib therapy. A more recent study, assessing 18 F-FDG PET-CT in 23 patients with NSCLC who received neoadjuvant EGFR-TKI, found that metabolic response after 7 days could predict pathological response . These results indicate a need for additional prospective studies to confirm whether change in tumor 18 F-FDG uptake after 2 days of treatment with an EGFR-TKI is an early sensitive marker of its effectiveness.
To investigate whether 18 F-FDG PET-CT can predict pathological responses after 2 days of gefitinib treatment and to determine the optimal cutoff value of 18 F-FDG uptake for detecting sensitivity to treatment, we assessed the relationship between gefitinib treatment and 18 F-FDG uptake, as well as between changes in 18 F-FDG uptake and tumor pathology in human tumor-bearing mice.
All animal experiments were approved by the PUMA Institutional Animal Research Committee. This study used 26 female Balb/c nude mice 6 to 8 weeks old and weighing 20 to 24 g.
The human A431 epidermoid carcinoma and A549 lung adenocarcinoma cell lines were generously provided by the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Comparative Medical Center, Peking Union Medical College. A431 cells, in which the wild-type EGFR gene is amplified and large amounts of the protein expressed, are sensitive to EGFR-TKIs . In contrast, A549 cells, which express wild-type EGFR, have a Ras mutation responsible for resistance to EGFR-TKIs.
All cells were grown in DMEM containing 10% fetal calf serum, 100 IU/mL penicillin, and 100 μg/mL streptomycin at 37°C in an atmosphere containing 5% CO2. Each mouse was inoculated subcutaneously in the right flank with 2 × 107 A431 or A549 cells.
Sixteen mice were implanted with A431 cells and ten with A549 cells. After the tumors had grown to an approximate size of 150 mm3, each group was randomly divided into two subgroups. Ten A431-implanted and five A549-implanted mice were intragastrically administered 100 mg/kg/day gefitinib, whereas six and five mice, respectively, were administered sterile water, as control. 18 F-FDG microPET-CT was performed the day before gefitinib administration (day 0) and on days 2, 7, and 14. The mice were subsequently sacrificed, and the tumor tissues rapidly resected. Tumors that had decreased in size ≥20% on day 14 were regarded as sensitive group; those that remained unchanged in size or had increased slowly, to a size smaller than that in the control group, were regarded as stable; and those that had increased to a size not significantly different from that of the control group were regarded as resistant.
18 F-FDG microPET-CT imaging
18 F-FDG was kindly provided by the PET-CT Center, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College. The Siemens Inveon combined microPET-CT scanner (Siemens Preclinical Solution USA, Inc., Knoxville, TN, USA) was provided by the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Comparative Medical Center, Peking Union Medical College. MicroCT scans were performed with an X-ray tube voltage of 80 kV, a current of 500 μA, an exposure time of 130 ms, and 120 rotation steps. The mice were anesthetized with isoflurane (2% in 100% oxygen) and, 10 min later, were injected intravenously with 290 ~ 320 μCi of 18 F-FDG in 200 μL saline. Imaging was started 60 min later. During scanning, each mouse was placed prone on the examination bed, and isoflurane (2% in 100% oxygen), with anesthesia maintained and lasting for 20 min. All microPET data were reconstructed with the filtered back-projection reconstruction algorithm.
Quantitative image analysis
Images were analyzed with the Inveon Research Workplace (Siemens, Erlangen, Germany). Regions of interest (ROIs) were drawn manually following qualitative assessment of the entire tumor. The maximal percentage of injected dose per gram of tissue (%ID/gmax) was determined using ROIs drawn around areas of increased tracer accumulation on serial microPET images . Tumor volume was determined by summation of voxels within the tomographic planes on serial CT images. The tumor volume response to therapy was expressed as ΔVolumeday n = [(Volumeday n − Volumeday 0)/Volumeday 0] × 100%, and the %ID/gmax response as Δ%ID/gmax day n = [(%ID/gmax day n − %ID/gmax day 0)/%ID/gmax day 0] × 100%, as described . All images were traced by an investigator blinded to treatment assignment.
Following tumor resection, each was cut open across its maximum dimension, fixed in 10% formalin, embedded in paraffin, sectioned at 4 mm thick with a microtome (RM2255, Leica Biosystems, Nussloch, Germany), and stained with hematoxylin and eosin. Pictures taken at high magnification (×200) were analyzed using Image-Pro Plus 6.0 professional image analysis software . On each histopathologic slide, five high-power fields were randomly chosen for counting (one each in the upper left, upper right, lower left, lower right, and middle). Necrotic areas were measured, and the necrotic fraction of each field was expressed as a percentage.
Results were presented as mean ± SD. Tumor responses in each group were evaluated by ANOVA. Statistical analyses were performed to correlate the percent necrosis per specimen with the change in %ID/gmax day 14. The areas under the receiver operating characteristic (ROC) curves (area under the curve, AUC) of %ID/gmax or Δ%ID/gmax on days 2, 7, and 14 were calculated by using a nonparametric method to assess whether an AUC of 0.5 for %ID/gmax or Δ%ID/gmax could discriminate between tumors sensitive and stable to gefitinib and to determine the possible AUC cutoff points for %ID/gmax and Δ%ID/gmax. P values less than 0.05 were considered statistically significant. Data from A431 and A549 tumors were analyzed independently.
Changes in tumor volume on microCT
Before gefitinib treatment, there were no significant differences in the volumes of A431 (n = 16) and A549 tumors (n = 10) [(201.54 ± 40.38 mm3) vs. (213.40 ± 69.23 mm3), P = 0.092]. Measurement of A431 tumor volume after 14 days of gefitinib treatment showed that six of these tumors were sensitive, four were stable, and none was resistant to gefitinib treatment. Before treatment, the mean volume of tumors found to be sensitive (215.78 ± 33.57 mm3) and stable (193.45 ± 42.81 mm3) to gefitinib was similar to that in untreated mice (192.70 ± 42.71 mm3). On day 2, the changes in mean tumor volume in these three groups were −12.13% ± 6.79%, 3.22% ± 6.79%, and 70.28% ± 30.81%, respectively, with no significant difference between the sensitive and stable groups (P = 0.169). On day 7, the changes from baseline in mean tumor volumes were −34.01% ± 7.17%, 12.02% ± 14.92%, and 229.65% ± 50.85%, respectively, with gefitinib-sensitive tumors being significantly smaller than gefitinib-stable (P = 0.034) and untreated (P = 0.000) tumors. On day 14, mean tumor volumes in these three groups were 143.65 ± 21.73, 264.90 ± 73.35, and 852.48 ± 99.42 mm3, respectively, corresponding to mean changes from baseline of −32.97% ± 7.91% (P = 0.047), 35.91% ± 18.51% (P = 0.000), and 357.21% ± 83.09% (P = 0.000), respectively (Figure 1).
Examination of tumor volume in the mice implanted with A549 cells and treated for 14 days showed that none was sensitive or stable to gefitinib, whereas five were resistant. Before treatment, the mean volumes of A549 tumors were treated, and untreated tumors were 240.10 ± 40.01 and 186.70 ± 86.02 mm3 (P = 0.125), respectively. The mean changes in tumor volume were 7.92% ± 11.64% and 11.47% ± 6.16% (P = 0.739), respectively, on day 2; 25.91% ± 18.47% and 50.03% ± 36.22% on day 7 (P = 0.235), respectively; and 47.70% ± 28.19% and 91.93% ± 56.55% (P = 0.174), respectively, on day 14. A549 tumor volumes before and after treatment did not differ significantly between gefitinib-treated and untreated mice groups at these time points (P > 0.05).
Changes in 18 F-FDG uptake on microPET
18 F-FDG uptake by A431 and A549 tumors prior to treatment differed significantly (P = 0.001). Before treatment, 18 F-FDG uptake by A431 tumors sensitive and stable to gefitinib and by untreated tumors was similar (Figure 2). After 2 days of gefitinib treatment, the %ID/gmax decreased markedly in the gefitinib-sensitive group (−30.92% ± 6.66%) and slightly in the gefitinib-stable group (−5.68% ± 6.95%), but increased in the untreated group (7.72% ± 3.85%) (P = 0.000 for each pairwise comparison). At all time points, there were significant differences in changes of tumor 18 F-FDG uptake. %ID/gmax gradually increased in the untreated group, but decreased slightly after day 7 (Figure 3).
In contrast, 18 F-FDG uptake by A549 tumors did not differ significantly in gefitinib-treated and untreated mice (Figure 4). The %ID/gmax of A549 tumors in both groups gradually increased over time, but decreased slightly after day 7.
ROC curve analysis of FDG uptake by A431 tumors
ROC curve analysis was performed to assess whether %ID/gmax or Δ%ID/gmax could discriminate between tumors sensitive and stable to gefitinib and to explore the possible threshold of %ID/gmax or Δ%ID/gmax that could accurately predict response to gefitinib. The Δ%ID/gmax of these tumors on days 2, 7, and 14 monitored treatment sensitivity (AUC = 1.000, P = 0.011 each). However, %ID/gmax of A431 tumors on days 2, 7, and 14 failed to differentiate between tumors sensitive and stable to gefitinib, with AUCs of 0.792 (P = 0.136), 0.667 (P = 0.394), and 0.813 (P = 0.110), respectively. Threshold with the maximum Youden index was used to calculate the sensitivity and specificity of this parameter. The cutoff point of Δ%ID/gmax on day 2 was −16.0%, which had a 100% sensitivity and a 100% specificity for predicting sensitivity to gefitinib.
Semiquantitative analysis of histopathologic findings
On day 14, necrosis was obvious in all three groups of A431 tumors, but necrotic areas were significantly larger in gefitinib-sensitive (90.57% ± 4.77%) than in gefitinib-stable (79.90% ± 7.76%, P = 0.045) and untreated (69.04% ± 7.80%, P = 0.000) tumors, as well as being significantly larger in gefitinib-stable than in untreated tumors (P = 0.042). In A549 tumors, the mean percent necrosis on day 14 was similar in gefitinib-treated (66.95% ± 9.06%) and untreated (65.66% ± 9.24%) mice (P = 0.795).
Small-molecule EGFR-TKI drugs have shown survival benefits in certain patient subpopulations, including female gender, Asian ethnicity, non-smokers, adenocarcinoma, and specific mutations of the EGFR kinase domain [3,5]. Conversely, these characteristics are absent from a sizable subgroup of patients with tumors that do respond to EGFR-TKIs. Thus, it is very difficult to predict the outcomes of EGFR-TKI therapy based on patient and tumor factors alone. 18 F-FDG PET may therefore be an alternative method of predicting tumor response, by measuring early changes in tumor uptake of 18 F-FDG. This study showed that 18 F-FDG uptake by A431 xenografts decreased after only 2 days of treatment, consisting of two oral doses of gefitinib. After 14 days of treatment, the tumor volume of A431 xenografts decreased or remained stable, while the mean percent tumor necrosis differed significantly in gefitinib-treated and untreated mice. Conversely, treatment of gefitinib-resistant A549 xenografts resulted in an increase, not a decrease, in FDG uptake during the course of therapy, with the mean volume and percent necrosis of tumors not differing significantly in gefitinib-treated and untreated mice after 14 days. These findings suggest that decreased 18 F-FDG uptake, starting after only 2 days of treatment, could reflect the volumetric and pathological changes observed after 14 days.
SUV of 18 F-FDG has been used to differentiate between benign and malignant tumors and to monitor responses to various treatments . Among the factors reported to correlate with SUV are tumor histological type, degree of differentiation, and tumor cell proliferation . We also found that 18 F-FDG uptake by A431- and A549-generated tumor differed significantly before therapy. The volume of A431 tumor xenografts decreased or remained stable after 14 days of treatment, whereas the volume of A549 tumors was similar in gefitinib-treated and untreated mice. Both cell lines express wild-type EGFR, but this gene is amplified and overexpressed in A431 cells, explaining their higher drug sensitivity, whereas A549 cells have a Ras mutation that is responsible for resistance.
Changes in tumor 18 F-FDG uptake from baseline have been used to evaluate responses to treatment and predict survival. For example, chemotherapy-induced changes in glucose metabolism were found to be highly predictive of survival in 50 patients with advanced rectal carcinoma . A study of 50 consecutive patients with locally advanced NSCLC who received induction chemotherapy or chemoradiotherapy found that a decrease in SUV from baseline to after three chemotherapy cycles was correlated with histopathologic response and prognosis . Change in tumor 18 F-FDG uptake was a better predictor of prognosis than in tumor 18 F-FDG uptake itself, since the latter is a momentary measurement. Since 18 F-FDG uptake varies widely among patients, a comparison with pre-treatment 18 F-FDG uptake could be used to monitor changes in tumor metabolic activity. Similarly, we found that A431 tumor 18 F-FDG uptake on days 2, 7, and 14 did not differ significantly in tumors sensitive and stable to treatment and in untreated tumors, whereas changes in tumor 18 F-FDG uptake differed significantly in all three groups. These results showed that changes in 18 F-FDG uptake reflected the dynamic response of tumors to treatment and provided better and more personalized information than a single determination of 18 F-FDG uptake. Changes in 18 F-FDG uptake may be more reliable in assessing response to treatment, guiding individual treatments, and evaluating therapeutic efficacy and patient prognosis.
A study of changes in tumor 18 F-FDG uptake from before to after 7 days of preoperative neoadjuvant EGFR-TKI treatment in 23 patients with NSCLC found that a ≥ −25% change in 18 F-FDG uptake 7 days after treatment could predict tumor remission (histopathological response) and increased tumor necrosis . Our histopathologic analysis showed that the necrotic areas of tumors sensitive and stable to gefitinib differed significantly from each other and from necrotic areas in untreated tumors. After 2 days of gefitinib administration, sensitive tumors showed a 30% decrease in metabolic activity, whereas stable tumors showed <10% decrease, indicating that changes in 18 F-FDG can predict pathological response and the effectiveness of gefitinib targeted therapy. Early changes in tumor 18 F-FDG uptake have been closely related with sensitivity to therapy and prognosis [21-23]. However, specific criteria to determine early 18 F-FDG PET response have not yet been defined, because of the involvement of many factors, such as tumor type, size, cell proliferation and diversity, time of evaluation, and inter-individual differences. A study of changes in 18 F-FDG uptake from before to after 14 days of neoadjuvant chemotherapy in patients with gastric cancer proposed a 35% reduction in 18 F-FDG uptake as a standard of treatment response and good prognosis . The results of the PERCIST study recommended that a ≥30% decrease in tumor 18 F-FDG uptake after 4 weeks of treatment be a criterion for solid tumor remission . Similarly, a 18 F-FDG PET evaluation of five NSCLC patients before and 2 days after the initiation of gefitinib therapy found that tumor uptake of 18 F-FDG was reduced 26% to 43% in patients who benefited from treatment . An investigation of changes in 18 F-FDG uptake over 2 days in 20 patients with lung adenocarcinoma receiving gefitinib therapy found that a 25% cutoff of SUV reduction was not significantly associated with PFS (P = 0.095) , whereas a 20% cutoff showed a significant relationship between metabolic response and longer PFS (P < 0.0001). The threshold of 18 F-FDG uptake changes determined by ROC curve analysis in the current study was a 16.0% reduction on day 2. However, mean Δ%ID/gmax on day 2 was 7.72% ± 3.85% in untreated mice, similar to the coefficient of variation of 18 F-FDG uptake threshold and likely due to high experimental variability.
We observed that untreated tumors were several times larger on day 14 than before treatment, while tumor uptake had decreased after 7 days. Rapidly growing transplanted tumors may not be provided with sufficient blood supply by the host. However, metabolic uptake is associated with tumor blood supply, not tumor volume , which may explain the reduction in %ID/gmax on day 14.
Although these results indicate that 18 F-FDG PET can be used to monitor tumor response to EGFR-TKIs, several limitations should be noted. First, both the A431 and A549 cell lines express the wild-type EGFR. Additional studies are needed to assess mice bearing human tumors expressing EGFR with kinase domain mutations. Animal experiments provided a rigorous test of our hypotheses, but the clinical complexity of inter-individual differences and the cutoff value for 18 F-FDG uptake indicating clinical benefits from treatment required determination. However, threshold values are highly dependent on the number of subcutaneously injected tumor cells. For example, tumor cells expressing mutated EGFR may have different thresholds of changes in 18 F-FDG uptake at early time points. In addition, human cancers are more complex and heterogeneous than mouse tumor xenografts. Other clinically relevant factors may be associated with early changes in tumor 18 F-FDG uptake during gefitinib treatment. Therefore, changes in 18 F-FDG uptake may not be as dramatic in patients as in mouse tumor xenografts.
Our findings suggest that response to gefitinib treatment, as assessed by 18 F-FDG PET, could help identify treatment sensitive tumors by their significant decrease in glucose metabolism. 18 F-FDG PET-CT is a sensitive and noninvasive method that may enable the selection of patients likely to benefit from gefitinib treatment. Confirming that reduced 18 F-FDG uptake could predict tumor response to gefitinib at early time points allowing the more sensitive detection of gefitinib-sensitive tumors and reduce drug side effects in clinical trials. Further studies, however, are needed to determine the optimal response criteria for various target therapies.
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21:2237–46.
Cohen EEW, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005;11:8105–8.
Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77–85.
Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38 Suppl 5:S60–5.
Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 2005;11:1167–73.
He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res. 2012;18:1790–7.
van Krieken JHJM, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453:417–31.
Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11:2879–82.
Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18 F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366–72.
Vliegen RFA, Beets-Tan RG, Vanhauten B, Driessen A, Oellers M, Kessels AG, et al. Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer? Strahlenther Onkol. 2008;184:457–64.
Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18 F-FDG PET. J Nucl Med. 2005;46:1144–50.
Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659–67.
Takahashi R, Hirata H, Tachibana I, Shimosegawa E, Inoue A, Nagatomo I, et al. Early [18 F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res. 2012;18:220–8.
Aukema TS, Kappers I, Olmos RAV, Codrington HE, van Tinteren H, van Pel R, et al. NEL Study Group: is 18 F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med. 2010;51:1344–8.
Aliaga A, Rousseau JA, Cadorette J, Croteau É, van Lier JE, Lecomte R, et al. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol. 2007;9:144–50.
Gan SY, Zhong XY, Xie SM, Li SM, Peng H, Luo F. Expression and significance of tumor drug resistance related proteins and beta-catenin in esophageal squamous cell carcinoma. Chin J Cancer. 2010;29:300–5.
Almuhaideb A, Papathanasiou N, Bomanji J. 18 F-FDG PET/CT imaging in oncology. Ann Saudi Med. 2011;31:3–13.
Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, et al. Correlation of 18 F-FLT and 18 F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610–6.
de Geus-Oei LF, van Laarhoven HWM, Visser EP, Hermsen R, van Hoorn BA, Kamm YJL, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2008;19:348–52.
Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, et al. Value of 18 F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res. 2006;12:97–106.
Tsutani Y, Miyata Y, Misumi K, Ikeda T, Mimura T, Hihara J, et al. Difference in prognostic significance of maximum standardized uptake value on [18 F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol. 2011;41:890–6.
Takeda A, Yokosuka N, Ohashi T, Kunieda E, Fujii H, Aoki Y, et al. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). Radiother Oncol. 2011;101:291–7.
Kitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y, Sugimura K. Prognostic significance of SUVmax (maximum standardized uptake value) measured by [18 F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 2012;39:840–5.
Wieder HA, Beer AJ, Lordick F, Ott K, Fischer M, Rummeny EJ, et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med. 2005;46:2029–34.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50.
Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer. 2008;59:203–10.
Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging. 2003;30:274–80.
We thank Dr. Yun-Zhou Gao for helping with our histopathologic experiments and providing the Image-Pro Plus 6.0 professional image analysis software. Histopathologic examinations were performed at the Institute of Basic Medical Sciences (IBMS) of the Chinese Academy of Medical Sciences (CAMS) and the School of Basic Medicine (SBM) of Peking Union Medical College (PUMC).
The authors declare that they have no competing interests.
NW and LNZ designed the study and revised the draft manuscript and subsequent manuscripts. YL helped to analyze the imaging data. KG, XYL, and LFZ helped to prepare the experiment and obtain and deal with the experimental data. All authors revised the article and approved the final version.